» Articles » PMID: 37049792

DNA Binding and Cleavage, Stopped-Flow Kinetic, Mechanistic, and Molecular Docking Studies of Cationic Ruthenium(II) Nitrosyl Complexes Containing "NS" Core

Overview
Journal Molecules
Publisher MDPI
Specialty Biology
Date 2023 Apr 13
PMID 37049792
Authors
Affiliations
Soon will be listed here.
Abstract

This work aimed to evaluate in vitro DNA binding mechanistically of cationic nitrosyl ruthenium complex [RuNOTSP] and its ligand (TSPH) in detail, correlate the findings with cleavage activity, and draw conclusions about the impact of the metal center. Theoretical studies were performed for [RuNOTSP], TSPH, and its anion TSP using DFT/B3LYP theory to calculate optimized energy, binding energy, and chemical reactivity. Since nearly all medications function by attaching to a particular protein or DNA, the in vitro calf thymus DNA (ctDNA) binding studies of [RuNOTSP] and TSPH with ctDNA were examined mechanistically using a variety of biophysical techniques. Fluorescence experiments showed that both compounds effectively bind to ctDNA through intercalative/electrostatic interactions via the DNA helix's phosphate backbone. The intrinsic binding constants (K), (2.4 ± 0.2) × 10 M ([RuNOTSP]) and (1.9 ± 0.3) × 10 M (TSPH), as well as the enhancement dynamic constants (K), (3.3 ± 0.3) × 10 M ([RuNOTSP]) and (2.6 ± 0.2) × 10 M (TSPH), reveal that [RuNOTSP] has a greater binding propensity for DNA compared to TSPH. Stopped-flow investigations showed that both [RuNOTSP] and TSPH bind through two reversible steps: a fast second-order binding, followed by a slow first-order isomerization reaction via a static quenching mechanism. For the first and second steps of [RuNOTSP] and TSPH, the detailed binding parameters were established. The total binding constants for [RuNOTSP] (K = 43.7 M, K = 2.3 × 10 M, ΔG = -36.6 kJ mol) and TSPH (K = 15.1 M, K = 66 × 10 M, ΔG = -19 kJ mol) revealed that the relative reactivity is approximately ([RuNOTSP])/(TSPH) = 3/1. The significantly negative ΔG values are consistent with a spontaneous binding reaction to both [RuNOTSP] and TSPH, with the former being very favorable. The findings showed that the Ru(II) center had an effect on the reaction rate but not on the mechanism and that the cationic [RuNOTSP] was a more highly effective DNA binder than the ligand TSPH via strong electrostatic interaction with the phosphate end of DNA. Because of its higher DNA binding affinity, cationic [RuNOTSP] demonstrated higher cleavage efficiency towards the minor groove of pBR322 DNA via the hydrolytic pathway than TSPH, revealing the synergy effect of TSPH in the form of the complex. Furthermore, the mode of interaction of both compounds with ctDNA has also been supported by molecular docking.

Citing Articles

Adsorption Behaviors of ctDNA and Biological Activities Based on Polyvinyl Alcohol/Polyethylene Glycol/Quaternized Chitosan Composite Hydrogel.

Fu L, Liu K, Yang J, Zhao Y, Wang Z, Tang D Molecules. 2024; 29(23).

PMID: 39683926 PMC: 11643572. DOI: 10.3390/molecules29235770.


Hydroxychloroquine-Loaded Chitosan Nanoparticles Induce Anticancer Activity in A549 Lung Cancer Cells: Design, BSA Binding, Molecular Docking, Mechanistic, and Biological Evaluation.

Elshami F, Shereef H, M El-Mehasseb I, Shaban S, van Eldik R Int J Mol Sci. 2023; 24(18).

PMID: 37762406 PMC: 10531786. DOI: 10.3390/ijms241814103.

References
1.
Tabassum S, Zaki M, Arjmand F, Ahmad I . Synthesis of heterobimetallic complexes: in vitro DNA binding, cleavage and antimicrobial studies. J Photochem Photobiol B. 2012; 114:108-18. DOI: 10.1016/j.jphotobiol.2012.05.017. View

2.
Hu X, Luo Q, Qin Y, Wu Y, Liu X . DNA Interaction, DNA Photocleavage, Photocytotoxicity In Vitro, and Molecular Docking of Naphthyl-Appended Ruthenium Complexes. Molecules. 2022; 27(12). PMC: 9227816. DOI: 10.3390/molecules27123676. View

3.
Zhang C, Xu C, Gao X, Yao Q . Platinum-based drugs for cancer therapy and anti-tumor strategies. Theranostics. 2022; 12(5):2115-2132. PMC: 8899578. DOI: 10.7150/thno.69424. View

4.
Sava G, Bergamo A, Dyson P . Metal-based antitumour drugs in the post-genomic era: what comes next?. Dalton Trans. 2011; 40(36):9069-75. DOI: 10.1039/c1dt10522a. View

5.
Chen W, Song X, He S, Sun J, Chen J, Wu T . Ru(II) complexes bearing guanidinium ligands as potent anticancer agents. J Inorg Biochem. 2016; 164:91-98. DOI: 10.1016/j.jinorgbio.2016.09.004. View